Abstract
BackgroundPeptides have recently become attractive for therapeutic applications. However, efficient production of medium- to large-sized peptides (30–100 amino acids [aa]) remains challenging both by recombinant and chemical synthesis. We previously reported the formation of active enzyme aggregates in Escherichia coli cells induced by the short β-structured peptide ELK16 (LELELKLKLELELKLK) and developed a streamlined protein expression and purification approach. In this approach, a cleavable self-aggregating tag (cSAT) consisting of an intein molecule and ELK16 was used to release the recombinant peptides with reasonable purity from active aggregates.ResultsIn this work, we extended the cSAT approach to a generalized expression and purification solution for a set of medium- to large-sized peptides with important therapeutic uses, including human glucagon-like peptide 1 (31 aa), B-type natriuretic peptide (32 aa), exendin 4 (39 aa), chemokine (C–C motif) ligand 5 (also known as RANTES, 66 aa), stromal cell-derived factor 1α (67 aa), insulin-like growth factor 1 (70 aa), and leptin (146 aa). After intein-mediated cleavage, the soluble peptides were released directly into the supernatant while insoluble peptides could be refolded and purified by reverse phase high-performance liquid chromatography. Additionally, an N-terminal thioredoxin tag was added upstream of the target peptides, which can be removed by enterokinase cleavage, generating native N-terminus for target peptides. Final yields of the peptides ranged from 0.1 to 1.8 μg/mg wet cell weight at laboratory scale.ConclusionsThe approach described in this study provides a fast and efficient route to express and purify peptides that are difficult or expensive to produce by chemical synthesis or by ordinary recombinant methods. It is particularly well suited for large peptides, peptides likely to be degraded, and peptides that have toxic effects on the host. It can greatly reduce the cost and time of downstream processing, and thus may be useful for both industrial manufacture and laboratory applications.Electronic supplementary materialThe online version of this article (doi:10.1186/s12934-016-0534-3) contains supplementary material, which is available to authorized users.
Highlights
Peptides have recently become attractive for therapeutic applications
We further extended the approach to successfully produce several therapeutically important peptides with lengths ranging from 30 to over 100 aa in E. coli cells, including the glucagon-like peptide 1 (GLP-1, aa) [22], B-type natriuretic peptide (BNP, aa) [23], exendin 4 (Ex-4, 39 aa) [24], chemokine (C–C motif ) ligand 5 (CCL5, known as RANTES, aa) [25], stromal cell-derived factor 1α (SDF-1α, aa) [26], insulin-like growth factor 1 (IGF-1, 70 aa) [27], and leptin (146 aa) [28]
As illustrated by SDF1-α, we discovered previously that the E. coli strain BL21(DE3) harboring the plasmid pET30a with SDF1-α sequence inserted in the MCS failed to produce the target band on SDS-PAGE and the Conclusions Currently, downstream processing represents a major factor in terms of time and cost for the manufacturing of recombinant peptide or protein biopharmaceuticals
Summary
Peptides have recently become attractive for therapeutic applications. efficient production of medium- to large-sized peptides (30–100 amino acids [aa]) remains challenging both by recombinant and chemical synthesis. We previously reported the formation of active enzyme aggregates in Escherichia coli cells induced by the short β-structured peptide ELK16 (LELELKLKLELELKLK) and developed a streamlined protein expression and purification approach. In this approach, a cleavable self-aggregating tag (cSAT) consisting of an intein molecule and ELK16 was used to release the recombinant peptides with reasonable purity from active aggregates. We reported that C-terminal fusions of the short β-structured selfassembling peptide ELK16 (LELELKLKLELELKLK) can induce the formation of highly active enzyme aggregates [20] Based on this finding, we designed a streamlined protein expression and purification approach. This single-step purification approach is capable of producing proteins with high yield and reasonable purity while reducing the cost and time required for purification [21]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.